Prevalence of Chronic Rhinosinusitis in Cystic Fibrosis

Aim of the study is to detect the prevalence of chronic rhinosinusitis and the colonisation with Pseudomonas aerug. in the upper airways in patients with cystic fibrosis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cystic Fibrosis Congenital, Hereditary, and Neonatal Diseases and Abnormalities Digestive System Diseases Genetic Diseases, Inborn Infant, Newborn, Diseases Infections Lung Diseases Nose Diseases Otorhinolaryngologic Diseases Pancreatic Diseases Paranasal Sinus Diseases Respiratory Tract Diseases Respiratory Tract Infections Sinusitis

Sex eligibility

All sexes

Study type

Observational

Primary location

Friedrich-Schiller-Universität

Jena, Thuringia, 07740, Germany

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Subject has a confirmed diagnosis of cystic fibrosis

Exclusion criteria

current systemic therapy against Pseudomonas aeruginosa

Treatment and study plan

Assessment of upper and lower airway colonization, sinonasal symptoms, history, rhinoscopy and rhinomanometry.

Other

Other names: nasal lavage and induced sputum

Primary outcomes

Pathogen colonization in upper and lower airways

Time frame: 3yrs
Sinonasal symptoms (SNOT-20)

Time frame: 3 yrs
rhinomanometry and rhinoscopy

Time frame: 3yrs

Sponsors and collaborators

Lead sponsor

University of Jena

Other

Registry information

Important dates

Study start: 2005
Study completion: 2007
First posted: Dec 16, 2005
Registry last updated: Dec 4, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed